NCT07119450

The Study of [14C] GZR18

A Mass Balance Study of [14C] GZR18 in Chinese Overweight or Obese Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Gan & Lee Pharmaceuticals. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This trial is a Single-center, non-randomized, open-label, single-dose Mass Balance Study. The study period of each subject consists of a screening period (D-21 to D-2), a baseline period (D-2 to D-1), a dosing and routine collection period (D1 to D36) and an intermittent collection and follow-up period (D36 to D78, during which subjects should visit the hospital once a week, 6 visits in total).

Conditions

• Overweight
• Obese
• Obesity

Interventions

Type	Name	Description
DRUG	GZR18 injection、[14C]GZR18 injection	Participants will get a single dose of \[14C\]GZR18 injection

Timeline

• Start date: 2025-05-07
• Primary completion: 2025-08-13
• Completion: 2025-08-13
• First posted: 2025-08-13
• Last updated: 2025-11-21

Locations

1 site across 1 country: China